S&P Futures
4,569.00 +9.75 (+0.21%) Dow Futures
35,658.00 +170.00 (+0.48%) Nasdaq Futures
16,062.00 +38.25 (+0.24%) Russell 2000 Futures
1,810.00 +4.20 (+0.23%) Crude Oil
79.46 +1.60 (+2.05%) Gold
2,058.20 -8.90 (-0.43%)
Core One Labs Inc. (COOL.CN)
Chart Events
Performance Outlook
| Previous Close | 0.2000 |
| Open | 0.0000 |
| Bid | 0.1900 x N/A |
| Ask | 0.2400 x N/A |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 10,258 |
| Market Cap | 11.186M |
| Beta (5Y Monthly) | 2.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for COOL.CN
Related Research
- ACCESSWIRE
Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
Core One Labs Inc. (CSE:COOL) (OTCQB:CLABF) (Frankfurt:LD6, WKN:A3CSSU), (the "Company" or "Core One") is delighted to announce the receipt of additional positive results from its second round ("Round 2") of Stage 1 animal model studies.
- ACCESSWIRE
Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
Core One Labs Inc.(CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6, WKN:A3CSSU) (the "Company" or "Core One") proudly announces a significant milestone in its pursuit of cutting-edge psychedelic research and development.
- ACCESSWIRE
Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
Core One Labs Inc.(CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6) (WKN:A3CSSU) (the "Company" or "Core One"), is excited to share positive results from its first round of Stage 1 animal model studies ("Round 1"), conducted by its research partners at the Universitat de Barcelona ("University of Barcelona" or the "University" or the "Investigators"), Barcelona, Spain, on behalf of the Company's wholly owned subsidiary, Akome Biotechnologies Inc. ("Akome").
